Clinical Trial Update: TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing lung stiffness reduction with TRIMBOW and RELVAR in COPD has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• RELVAR (fluticasone furoate/vilanterol)
• Trimbow (budesonide/formoterol/glycopyrronium)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD | Phase 4 | Status: WITHDRAWN